Nabriva Therapeutics plc

NasdaqCM:NBRV Stock Report

Mkt Cap: US$4.9m

We’ve recently updated our valuation analysis.

Nabriva Therapeutics Valuation

Is NBRV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NBRV?

Other financial metrics that can be useful for relative valuation.

NBRV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does NBRV's PS Ratio compare to its peers?

The above table shows the PS ratio for NBRV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.5x
STMH Stem Holdings
0.4xn/aUS$6.8m
CANB Can B
0.6xn/aUS$4.8m
SNES SenesTech
8.8x47.3%US$7.8m
BMMJ Body and Mind
0.3xn/aUS$9.6m
NBRV Nabriva Therapeutics
0.1x29.0%US$4.9m

Price-To-Sales vs Peers: NBRV is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (2.5x).


Price to Earnings Ratio vs Industry

How does NBRV's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.7%
n/an/an/a

Price-To-Sales vs Industry: NBRV is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Pharmaceuticals industry average (3x)


Price to Sales Ratio vs Fair Ratio

What is NBRV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NBRV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.1x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: NBRV is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).


Share Price vs Fair Value

What is the Fair Price of NBRV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NBRV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NBRV's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NBRV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.59
US$1.18
-26.1%
14.9%US$1.35US$1.00n/a2
Jan ’24US$1.89
US$8.00
+323.3%
0%US$8.00US$8.00n/a1
Dec ’23US$2.19
US$8.00
+265.3%
0%US$8.00US$8.00n/a1
Nov ’23US$2.58
US$18.00
+596.6%
0%US$18.00US$18.00n/a1
Oct ’23US$2.08
US$18.00
+765.4%
0%US$18.00US$18.00n/a1
Sep ’23US$4.00
US$50.00
+1,150.0%
0%US$50.00US$50.00n/a1
Aug ’23US$4.26
US$50.00
+1,073.0%
0%US$50.00US$50.00n/a1
Jul ’23US$4.50
US$50.00
+1,010.5%
0%US$50.00US$50.00n/a1
Jun ’23US$5.07
US$50.00
+886.2%
0%US$50.00US$50.00n/a1
May ’23US$7.83
US$50.00
+539.0%
0%US$50.00US$50.00n/a1
Apr ’23US$10.40
US$50.00
+380.9%
0%US$50.00US$50.00n/a1
Mar ’23US$11.10
US$100.00
+800.7%
0%US$100.00US$100.00n/a1
Feb ’23US$12.78
US$66.88
+423.5%
49.5%US$100.00US$33.75US$1.592
Jan ’23US$14.97
US$66.88
+346.7%
49.5%US$100.00US$33.75US$1.892
Dec ’22US$17.75
US$66.88
+276.8%
49.5%US$100.00US$33.75US$2.192
Nov ’22US$30.25
US$66.88
+121.1%
49.5%US$100.00US$33.75US$2.582
Oct ’22US$29.75
US$66.88
+124.8%
49.5%US$100.00US$33.75US$2.082
Sep ’22US$27.00
US$66.88
+147.7%
49.5%US$100.00US$33.75US$4.002
Aug ’22US$27.50
US$91.88
+234.1%
63.3%US$150.00US$33.75US$4.262
Jul ’22US$32.50
US$150.00
+361.5%
0%US$150.00US$150.00US$4.501
Jun ’22US$34.75
US$150.00
+331.7%
0%US$150.00US$150.00US$5.071
May ’22US$44.50
US$150.00
+237.1%
0%US$150.00US$150.00US$7.831
Apr ’22US$43.75
US$150.00
+242.9%
0%US$150.00US$150.00US$10.401
Mar ’22US$48.00
US$225.00
+368.8%
0%US$225.00US$225.00US$11.101
Feb ’22US$66.00
US$225.00
+240.9%
0%US$225.00US$225.00US$12.781

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies